Nutriband Inc. reported record revenue of $1,289,884 for the six months ended July 31, 2025, representing a 50.87% increase year-over-year. For the three months ended July 31, 2025, revenue reached $622,452, up 40.56% from the prior year, primarily driven by the Pocono Pharmaceuticals segment.
The company reported a net loss of $2.00 million for the three months ended July 31, 2025, and $3.39 million for the six months ended July 31, 2025. The net loss available to common stockholders was significantly impacted by a preferred shares dividend of $21.81 million.
As of July 31, 2025, Nutriband's cash reserves stood at $6.9 million, supporting the ongoing development and commercialization efforts for AVERSA™ Fentanyl. Progress continues on AVERSA Fentanyl development, with the NDA primarily relying on data from a single Phase 1 Human Abuse Potential study, and a Type C meeting with the FDA granted for September 18.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.